Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion
The firm's Shanghai-listed stock rose as much as 8.16% to reach its highest level since July 2021, while its Hong Kong-listed shares were up as much as 10.95% on Monday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
25 minutes ago
- Bloomberg
Asian Stocks Set for Subdued Open Ahead of Fed: Markets Wrap
Asian equities are set for a lackluster start ahead of the Federal Reserve's policy decision, with investors showing little enthusiasm for progress in US-China trade talks. Futures for Tokyo and Hong Kong equities pointed lower, while Sydney contracts were flat after the S&P 500 snapped a six-day rally, slipping 0.3%. Treasuries climbed, led by longer-dated notes, following a solid $44 billion sale. Oil held gains early Wednesday after President Donald Trump's reiteration that further levies on Russia remained on the table without a Ukraine truce.
Bloomberg
an hour ago
- Bloomberg
Trump to Get Last Word on China Truce Extension, Bessent Says
By and Rainier Harris Save Good morning. The US and China aren't done talking. Trump gives Russia 10 days to reach a Ukraine truce. And a mass shooting in Manhattan evokes grief and prompts tighter security. Listen to the day's top stories. The third round of US-China trade talks wrapped up without clarity on the fate of the tariff truce that's set to expire in two weeks. China's delegation earlier said a 90-day extension had been reached, but Treasury Secretary Scott Bessent said they 'jumped the gun a little' and that Donald Trump will make the final call. The president, returning from Scotland after dealing the EU a harsh blow in the trade war, said India may face a tariff rate of 20% to 25%.
Bloomberg
an hour ago
- Bloomberg
AstraZeneca's US Investment, Future of Psychedelic Therapy
On today's episode of Bloomberg Businessweek Daily with Tim Stenovec and Carol Massar, Pascal Soriot, Chief Executive Officer of AstraZeneca discusses the company's quarterly earnings. Kabir Nath, Chief Executive Officer of Compass Pathways, on the pursuit of FDA approval of the first psychedelic treatment for certain people living with depression. Also, Bloomberg's Molly Smith and Oliver Crook on US-China Trade talks and the FOMC meeting (Source: Bloomberg)
